On Friday, Deutsche Bank (ETR:DBKGn) issued a downgrade for AstraZeneca (NASDAQ:AZN) stock from Hold to Sell, adjusting the price target to £105.00 from the previous £110.00. The firm cited concerns over the pharmaceutical company's TROP2 asset datopotamab, initially hoped to be a significant breakthrough in lung cancer treatment.
The analyst from Deutsche Bank pointed to a series of events that have shifted perspectives on the drug's potential. Detailed data presented at the European Society for Medical Oncology (ESMO) 2023 conference, along with changing narratives on the risk-benefit balance and target population for both first and second-line treatments, have suggested possible regulatory challenges ahead.
This week's presentation of biomarker data did not alleviate these concerns but instead introduced new ones, according to the analyst. Datopotamab was seen as a crucial component of AstraZeneca's revenue guidance for the second half of the 2020s, but now its future seems uncertain.
The analyst expressed that the balance of risks and rewards for AstraZeneca's stock has become particularly challenging over a 6-12 month view. With a difficult FDA advisory committee meeting and drug review expected in December, coupled with potential downside risks to the fiscal year 2025 guidance, the analyst believes the current valuation does not reflect these concerns. The firm's projections remain significantly below the mid-term consensus and the company's own guidance.
In other recent news, AstraZeneca continues to make strides in its oncology pipeline. The pharmaceutical giant, in collaboration with Daiichi Sankyo, reported a trend toward improved overall survival in a Phase III trial for certain lung cancer patients using their drug datopotamab deruxtecan (Dato-DXd).
This follows AstraZeneca's IMFINZI (durvalumab) receiving FDA approval for treating adults with resectable early-stage non-small cell lung cancer, and gaining Priority Review status for treating limited-stage small cell lung cancer.
BMO Capital maintained a positive outlook on AstraZeneca shares, reiterating an Outperform rating, while Erste Group upgraded AstraZeneca's stock from Hold to Buy. TD Cowen and BofA Securities also maintained their Buy ratings for the company. These decisions were driven by the company's strong financial structure and above-average growth projection, despite potential approval risks for Dato-DXd.
In partnership with SOPHiA GENETICS, AstraZeneca plans to expand its liquid biopsy test MSK-ACCESS® to 20 global locations within the next year to enhance cancer diagnostics and treatment. Lastly, AstraZeneca secured €1.4 billion through a bond offering managed by notable financial institutions. These recent developments demonstrate AstraZeneca's ongoing advancements in the pharmaceutical industry.
InvestingPro Insights
Following Deutsche Bank's downgrade of AstraZeneca, investors may be seeking additional perspectives on the company's financial health and future prospects. According to InvestingPro data, AstraZeneca boasts a substantial market capitalization of $240.89 billion and a robust revenue growth of 10.45% in the last twelve months as of Q2 2024. Despite concerns raised about specific assets, the company has maintained a gross profit margin of 82.62%, underscoring its ability to retain earnings relative to revenue.
InvestingPro Tips indicate that net income is expected to grow this year, with two analysts having revised their earnings upwards for the upcoming period. This could signal confidence in the company's ability to navigate current challenges. Moreover, AstraZeneca has been a prominent player in the Pharmaceuticals industry and has upheld dividend payments for 32 consecutive years, which may be of interest to income-focused investors. It's worth noting that while the stock trades at a high Price / Book multiple of 6.09, it generally exhibits low price volatility.
For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available that delve into aspects such as the company's debt levels, cash flows, and earnings multiples. These insights can help investors form a well-rounded view of AstraZeneca's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.